Experts attribute the recent surge on factors like favorable market sentiment, robust domestic liquidity, and a strong ...

Can we develop chemical reactions that represent direct analogs to common design strategies? The answer to this question has created a movement of “molecular editing,” with distinct forms of ...

Editor Sabrina Pitre (Clown in a Cornfield) spoke to Bleeding Cool about breaking down Final Destination: Bloodlines most memorable scenes.

Quick-commerce platform Zepto, in an innovative collaboration with beauty giant Unilever’s Lakmé, has launched a unique out-of-home (OOH) campaign at Mumbai’s iconic Juhu Beach, leveraging the very ...

No exceptions, no excuses. So, platforms like Zepto, Blinkit, and Swiggy Instamart keep their main app clean for Play store compliance while offering a separate APK (a 'Lite' version of the app) from ...

The streets of Mumbai are heating up, and it is not because of the weather. It’s the cheeky billboards in the city turning heads, garnering attention, and sparking conversations. Libas and Zepto ...

Zepto has started monetising its user data beyond its own platform through a new partnership with global ad-tech firm The Trade Desk (TTD), according to a Livemint report. The quick commerce ...

To the editor: Finally, good news among the stream of doom and gloom coverage of what is happening in Los Angeles (“With a surging residency rate, this neighborhood is transforming L.A.,” June ...

Advertising technology firm The Trade Desk and quick commerce platform Zepto have announced a strategic partnership aimed at improving targeting precision on the open internet and providing measurable ...

Zepto, a fast-growing quick commerce platform in India, has partnered with global ad-tech giant The Trade Desk. The collaboration will allow brands to use shopping data on the platform for more ...

Eli Lilly & Co. agreed to buy Verve Therapeutics Inc., a US biotech that’s seeking to use gene editing to prevent clogged arteries, for as much as $1.3 billion.

Eli Lilly acquires Verve Therapeutics, Inc. for $1B to advance gene-editing therapies like VERVE-102, targeting ASCVD. Click for more on LLY and VERV.